Howard Hochster, MD, discusses the outcomes of the Keynote-177 study in metastatic CRC Published 2020-06-02 Download video MP4 360p Recommendations 09:01 Don’t Wake Up | Keeping Dormant Cancer Cells Asleep to Prevent Metastasis 18:46 Approach to the Exam for Parkinson's Disease 01:32 Johnetta Blakely, MD, considers how HEOR data influences payer decisions 03:05 Bo Gamble, speculates on the future of alternative payment models (APMs) 13:50 4 Tricks for when doctors gaslight you - Dr. Kaveh LIVE 07:36 PASS-01: Stratifying Pancreatic Adenocarcinoma Signature for Treatment 11:14 Why Is It Said That In Old Age, One Should Not Go Visiting Around? Reasons You Must Know. 02:14 Scientists Discover Robust Evidence That Chronic Fatigue Syndrome (ME/CFS) Is a Biological Illness 14:46 Excess Deaths at Night - Obstructive Sleep Apnea Explained Clearly 02:41 Surviving Gastric Cancer 13:55 Spinal or General Anesthesia for Hip Fracture (NEJM) 03:07 Lactose Intolerance vs. Milk Protein Allergy - Dr. Elaine Barfield & Shara Wagowski, RD 02:19 Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists 01:29 What happens when your nose runs 31:34 Medical Minute: Meningiomas 02:36 Kathy Oubre, MS, speculates on the future of biosimilars 02:13 Johnetta Blakely, MD, explains the role of HEOR as it contributes to value-based care 01:12 How much water should you drink a day? 02:22 Is Type 2 Diabetes Reversible? (excerpt) 03:04 Johnetta Blakely, MD, offers an example of how HEOR has impacted cancer care at Tennessee Oncology Similar videos 01:16 Howard Hochster MD, provides thoughts on potential practice changing results of the Keynote177 study 01:34 Howard Hochster, MD, Explains Colorectal Cancer Screening Guidelines 02:16 Alan Venook, MD, describes the potential practice changing results of the Keynote-177 study 08:40 Thierry Andre, ASCO20: Phase III KEYNOTE-177 Trial of Pembrolizumab in Metastatic Colorectal Cancer 06:57 KEYNOTE-177 discussion: chemo-immunotherapy, pseudoprogression & biomarkers 02:56 KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC 03:44 KEYNOTE-177 & CheckMate 142: checkpoint blockade in MSI-H/dMMR CRC 59:51 Redefining First- line Therapy in Metastatic Colon Cancer. The Keynote-177 Study. 01:03 Dr. Nelson on the CheckMate-142 Trial in MSI-H/dMMR mCRC 1:16:23 3.24 KEYNOTE-177 & Mathematic Models for Fighting COVID-19 with Dr. Wesley Pegden 24:05 What's New in Colorectal Cancer Treatment? by Michael Hall, MD, MS 02:32 Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC 01:34 Thierry Andre, MD, on evolution of I-O towards the first line treatment of colorectal cancer 02:12 Alan Venook, MD, considers how I-O is evolving towards the first line treatment of colorectal cancer 29:15 ICAHO20 - ASCO Direct™ Highlights - Dr. Axel Grothey - Colorectal Cancer 01:12 Salvatore Siena, MD, discusses the incidence of HER2+ patients amongst CRC patients 01:39 Alan Venook, MD, discusses next generation sequencing and mCRC treatment 01:25 Thierry Andre, MD, provides thoughts on how to identify patients with CRC unlikely to respond to I-O 01:26 Alan Venook, MD, provides thoughts on the clinical progress of trastuzumab-deruxtecan in GI cancers More results